Abstract:Therapeutic advances for neurological disorders are challenging due to limited accessibility of the human central nervous system and incomplete understanding of disease mechanisms. Many neurological diseases lack precision treatments, leading to significant disease burden and poor outcome for affected patients. Induced pluripotent stem cell (iPSC) technology provides human neuronal cells that facilitate disease modeling and development of therapies. The use of genome editing, in particular CRISPR-Cas9 technology, has extended the potential of iPSCs, generating new models for a number of disorders, including Alzheimers and Parkinson Disease. Editing of iPSCs, in particular with CRISPR-Cas9, allows generation of isogenic pairs, which differ only in the disease-causing mutation and share the same genetic background, for assessment of phenotypic differences and downstream effects. Moreover, genome-wide CRISPR screens allow high-throughput interrogation for genetic modifiers in neuronal phenotypes, leading to discovery of novel pathways, and identification of new therapeutic targets. CRISPR-Cas9 has now evolved beyond altering gene expression. Indeed, fusion of a defective Cas9 (dCas9) nuclease with transcriptional repressors or activation domains allows down-regulation or activation of gene expression (CRISPR interference, CRISPRi; CRISPR activation, CRISPRa). These new tools will improve disease modeling and facilitate CRISPR and cell-based therapies, as seen for epilepsy and Duchenne muscular dystrophy. Genome engineering holds huge promise for the future understanding and treatment of neurological disorders, but there are numerous barriers to overcome. The synergy of iPSC-based model systems and gene editing will play a vital role in the route to precision medicine and the clinical translation of genome editing-based therapies.

CRISPRi: a way to integrate iPSC-derived neuronal models

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Induced Pluripotent Stem Cells As a Disease Modeling and Drug Screening Platform

Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies

Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges

Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models

CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons

Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling

CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics

Modeling the complex genetic architectures of brain disease

Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases

Modeling neurological diseases using iPSC-derived neural cells

Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism

Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders

Understanding neural development and diseases using CRISPR screens in human pluripotent stem cell-derived cultures

Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening

Modeling Alzheimer’s disease with iPSC-derived brain cells

Human-induced pluripotent stem cells: potential for neurodegenerative diseases

[iPS cell technologies toward overcoming neurological diseases]

Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery

CRISPRi-based screens in iAssembloids to elucidate neuron-glia interactions